lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
For his contributions to the development and progress of Malaysia, Mahathir was honoured by his successor, Abdullah Badawi, with the title Bapa Pemodenan Malaysia (Father of Malaysia's Modernisation) after stepping down from office. The following year, Barisan Nasional leaders and members paid tribute to Mahathir during a dinner in Kuala Lumpur, acknowledging his remarkable contributions to the coalition and the nation.
=== Archers and Custodians of Dawn and Twilight === Kaya Fugeki (巫覡 花矢, Fugeki Kaya) The Archer of Dawn, her task is to bring the Day to Yamato. She is a 16 y/o high school student with a masculine way of speech, but no one knows she's the Goddess of the Day, except Yuzuru. She deeply cares for Yuzuru. She tries to force him to abandon his role as Guardian so that he can gain the freedom she lacks. Yuzuru Fugeki (巫覡 弓弦, Fugeki Yuzuru) The Archer of Dawn's Custodian. He decided to serve Kaya in place of his father. He is proud of his work and is fond of Kaya, but is annoyed that she is trying to force him to abandon his role as her Custodian. Kaguya Fugeki (巫覡 輝矢, Fugeki Kaguya) The Archer of Twilight, his task is to bring Night to Yamato. He fell into depression after his wife and his custodian, Eken, suddenly ran away from home. His feelings for Tsukihi are difficult to explain in words. Eken Fugeki (巫覡 慧剣, Fugeki Eken) The Archer of Twilight's Custodian. He respects Kaguya and they once lived together as father and son, but one day, he ran away.
== Development == Day of Defeat began development as a third-party Half-Life modification in 1999. In 2000, the mod’s development team started releasing closed alpha versions, eventually releasing Beta 1.0, the first public version, in January 2001. In the initial release of the modification, it included only four player classes: Light Infantry, Assault Infantry, Sniper, and Heavy Weapons, with each class having unique movement characteristics. This difference, however, was removed with the release of Beta 2.0 in February 2002. Beta 2.0 also introduced a new recoil and aiming system, significantly reduced accuracy while moving, added new weapons and machine gun classes with deployable bipods, and introduced prone and sprinting mechanics, resulting in major changes to the gameplay. In July 2002, Beta 3.0 was released with a new classes based around paratrooper maps, in which players would only respawn upon the beginning of a new round. While the first versions of Day of Defeat were distributed over the internet at no cost, the rights to the game were later purchased by Valve and the modding team hired. Valve then produced a stand-alone retail version of the game, published by Activision and released in May 2003. The retail version included a number of changes from the modification, including the addition of British Army, improved graphics and fifteen maps, nine of which were completely new.
Sources: en.wikipedia.org
=== Infection control concerns === Studies have shown that doctor's coats worn in hospitals can harbor contagions including MRSA. In 2007, the UK National Health Service (NHS) started banning long-sleeved coats. In 2009, the American Medical Association investigated banning coats with long sleeves to protect patients, but did not institute a ban. A study published in 2011 investigating the effectiveness of the NHS ban showed no statistical difference in contamination levels over an 8-hour period between residents wearing long-sleeved coats and those wearing short-sleeved scrubs. In an effort to reduce the contamination of healthcare uniforms, ASTM International is developing standards to specifically address liquid penetration resistance, liquid repellency, bacterial decontamination, and antimicrobial properties of such uniforms. The spread of white coat infection has been rampant and talked about in the scientific community. Indian physician Edmond Fernandes triggered a controversy in India and parts of South Asia by calling for a ban on white coats because of the spread of nosocomial infections.
It develops most often only after prolonged (months, years or even decades) exposure to antidopaminergics. Extrapyramidal side effects. Motor symptoms such as tremor, parkinsonism, involuntary movements, reduced ability to move one's voluntary muscles, etc. Unknown incidence or relationship to drug treatment adverse effects include:
== Interactions == Lenvatinib inhibits the liver enzyme CYP3A, which also happens to be a metabolic enzyme for the drug. It inhibits the UDP-glucuronosyltransferases UGT1A1 and UGT1A4. Lenvatinib induces CYP3A but not UGT1A1 and UGT1A4. Use of other drugs, especially ones metabolized by the liver enzyme CYP3A, should be monitored in case their plasma concentration changes. In vitro studies have shown that lenvatinib inhibits organic anion transporters 1 and 3 (OAT1 and OAT3). Sunitinib is metabolized in the liver by CYP3A4. It interacts with inducers and inhibitors of CYP3A4 leading to a decrease or increase in the plasma concentration of particular drugs metabolized by the same pathway. It will not change the amount of drug metabolized by the enzyme, because it does not inhibit or induce the enzyme directly. Sunitinib is a substrate of P-glycoprotein and ABCG2 transporters. It acts as an inhibitor for both transporters, especially for ABCG2. Therefore, drugs that are substrates of these carriers will have modified pharmacokinetics. Plasma concentration of sorafenib and paclitaxel may be increased when the drugs are co-administered along with carboplatin. This has no effect on carboplatin. It also increases the AUC of docetaxel, doxorubicin and irinotecan but decreases the AUC of fluorouracil and neomycin, so it is cautionary to administer sorafenib with these drugs as it may alter the plasma concentration. Sorafenib is metabolized by CYP3A4 and UGT1A9. This means that drugs metabolized by these pathways have to be carefully administered.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.